The fast-growing perimenopause supplement category has received strong validation from a comprehensive study demonstrating the benefits of the Xeya Ayurvedic herb shatavari (Asparagus racemosus).
Conducted with NXT USA’s branded ingredient, Xeya Modern Shatavari™, the research showed meaningful improvements across a wide range of menopausal symptoms, including hot flashes, menstrual discomfort and overall quality of life.
The double-blind, randomized, placebo-controlled study, published in Functional Foods in Health and Disease, utilized Xeya Modern Shatavari, which is standardized to a market-high 15% shatavarins. This high standardization allows for clinically effective support at remarkably low doses of just 50-100 mg, setting a new benchmark for the category.
“Women’s concerns have been neglected for too long. This study shows real benefits for women dealing with perimenopausal symptoms, dramatically improving quality of life for the participants,” said Eric Anderson, managing director of NXT USA in Metuchen, New Jersey.
“This is the NXT standard of comprehensive clinical evidence—incorporating our comprehensive ‘four pillars of validation’ in study design that measures patient reporting, physician assessment, biomarkers and physical tests. This is the most comprehensive study on shatavari published to date.”
77% improvement in symptoms
Participants taking 100 mg of Xeya experienced a significant 77.3% improvement in somatic symptoms—such as hot flashes, fatigue and sleep disturbances—and a 74.5% improvement in psychological symptoms, including mood swings, anxiety and brain fog, as measured by the Menopause Rating Scale, a tool widely used in clinical research and practice.
Xeya Modern Shatavari, at both 50 and 100 mg, significantly decreased the Menopausal Rating Scale, by 51.4% and 72.9%, respectively, compared to 22.8% in the placebo group. The Menstrual Symptoms Questionnaire score significantly improved by 166.7% and 178.8% in the 50-mg and 100-mg groups, respectively, compared to a 35.9% improvement in the placebo group. The Hot Flash Weekly Weighted Scores significantly dropped by 27.6% and 39.8% in the two treatment groups, respectively, compared to a 7.7% increase in the placebo group.
Shatavari, known as the queen of Ayurveda, balances female hormones. Hormone balance itself is another supplement category that is emerging in the larger women’s health arena. Hormone balancing has effects throughout women’s lives, from the first menstrual cycle through fertility and into perimenopause and menopause.
Study details
The 120-day study, conducted at Lifeline Hospital & Research Center in India, included 75 early perimenopausal women aged 40-50 years old with mild-to-moderate vasomotor symptoms like hot flashes and night sweats. Using both 50-mg and 100-mg doses of NXT USA’s Xeya Modern Shatavari, researchers found significantly positive effects on vasomotor symptoms, menstrual discomfort and hormonal dysregulation.
This was shown through an evaluation of symptom scores, reproductive hormone levels, ovarian follicle counts and patient-reported outcomes, ensuring its safety and tolerability over a 120-day period.
“These findings extend beyond traditional anecdotal or preclinical evidence,” researchers commented, “offering robust clinical support for shatavari as a natural, multi-targeted therapeutic option to promote women’s health.”
Menstrual symptoms, particularly spasmodic and congestive dysmenorrhea, showed marked improvement in the Xeya Modern Shatavari group.
The ovarian follicle count also significantly increased, by 34.4% and 51.9% in the two treatment arms, compared to no change in the placebo group.
Notably, dose-dependent modulation was observed for four separate hormones: follicle-stimulating hormone (FSH), luteinizing hormone (LH), anti-Müllerian hormone (AMH) and 17β-estradiol (E2). Skin and hair quality also improved.
“These findings align with a growing body of evidence supporting the adaptogenic and hormone-balancing effects of A. racemosus in women’s health,” concluded the research team, “reinforcing the feasibility of integrating [Xeya Modern Shatavari] as a bioactive ingredient in functional foods or dietary supplements designed for perimenopausal and menopausal support.”
Shatavari formula ingredients
Xeya Modern Shatavari is produced through traditional extraction methods using water and alcohol. Test methods are reproducible in labs, and batches are tested for consistency.
“This is what a modern extract should be,” said Anderson. “It’s a fully standardized extraction, giving a more concentrated, quality material.”
Prior clinical research on Xeya Modern Shatavari demonstrated benefits on key markers of reproductive and metabolic health in younger women with hormonal imbalances. More specifically, the study showed hormone-balancing effects with benefits for women aged 20-35 with polycystic ovary syndrome, or PCOS. It found support for menstrual cycle regularity, the maintenance of healthy hormone levels and the promotion of ovarian function and follicle health.
“Xeya was developed with the world class team at Laila Nutra. Their team has achieved impressive results via careful sourcing to science and validation, to bring Xeya Modern Shatavari to market,” Anderson added. “Having this study published on perimenopause is ideal timing because shatavari is emerging as the partner to ashwagandha—known as the king of Ayurveda—which has exploded in popularity the last few years. We expect shatavari to really take off this year to support women’s wellness across all age groups. This study provides supplement brands with the confidence to offer differentiated products that serve women of various age groups and demographics.”
Reference
1. Yadav P, et al. Clinical assessment of CL22209, a standardized proprietary extract of Asparagus racemosus, for mitigating vasomotor and menstrual symptoms in perimenopausal women: A randomized, double-blind, placebo-controlled study. FFHD. 2025;15(7):415-34. https://www.ffhdj.com/index.php/ffhd/article/view/1684. Accessed September 8, 2025.
